TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

AstraZeneca starts trial of COVID-19 antibody treatment

  • News Desk

    Reuters

  /   Tue, August 25, 2020   /   02:30 pm
AstraZeneca starts trial of COVID-19 antibody treatment A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014.AstraZeneca said on Tuesday it had begun testing an antibody-based treatment for the prevention and treatment of COVID-19, with the first participants dosed, adding to recent signs of progress on possible medical solutions to the disease. (Reuters/Phil Noble)

AstraZeneca said on Tuesday it had begun testing an antibody-based treatment for the prevention and treatment of COVID-19, with the first participants dosed, adding to recent signs of progress on possible medical solutions to the disease.

The British drugmaker, whose COVID-19 vaccine candidate is already among the most advanced, said the early-stage trial would evaluate if AZD7442, a combination of two monoclonal antibodies (mAbs), was safe and tolerable in up to 48 healthy participants between the ages of 18 and 55 years.

If the UK-based trial has a positive readout, AstraZeneca said it would proceed with larger, mid-to-late-stage trials to test AZD7442 as both a preventative treatment for the disease and a medicine for patients who have it.

mAbs mimic natural antibodies generated in the body to fight off infection and can be synthesized in the laboratory to treat diseases in patients and has been endorsed by top scientists. Current uses include treatment of some types of cancers.

London-listed AstraZeneca in June received $23.7 million in funding from US government agencies to advance development of antibody-based treatments for the novel coronavirus.

US based companies Regeneron and ELi Lilly are also testing mAbs-based treatments for COVID-19.